A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer - Drug Trials For Money

Experimental: Quadruplet regimen prior to resection for pancreatic cancer

Treatment of Canakinumab and Tislelizumab in Combination with Nab-Paclitaxel and Gemcitabine up to 4 cycles (4 months)

Drug: Canakinumab

250 mg subcutaneous injection in prefilled syringes on day 1 of every 28-day cycle

Other Name: ACZ885

Drug: Tislelizumab

300 mg in a liquid vial (concentrate for intravenous (i.v.) solution) on day 1 of every 28-day cycle

Drug: Nab-Paclitaxel

125 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle

Drug: Gemcitabine

1000 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.